Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill plus chemo aims to tackle tough pancreatic cancer

NCT ID NCT07562152

Disease control Sponsor: Immuneering Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 18, 2026 · Updated 18 times

Summary

This Phase 3 trial tests whether adding an experimental oral drug called atebimetinib to a modified chemotherapy regimen helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standard chemotherapy. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
atebimetinib (an experimental oral drug) combined with gemcitabine and nab-paclitaxel chemotherapy
What this could lead to
If successful, this could offer a new first-line treatment option that extends survival for people with metastatic pancreatic cancer.
What could go wrong
This is an early-stage Phase 3 trial, so results are not guaranteed. Adding a targeted drug to chemo may increase side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 510 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Feb 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Must be ≥18 years of age * Must have confirmed diagnosis according to AJCC staging as follows: * Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Participants must be treatment naive as follows: * First-line PDAC participants will have received no previous systemic anti-cancer therapy * Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria * Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values Exclusion Criteria: * Inability to swallow oral medications * Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma * Participants with only locally advanced disease * Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pancreatic adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm Neoplasm Metastasis pancreatic adenocarcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pancreatic adenocarcinoma Pancreatic adenocarcinoma metastatic Pancreatic cancer Pancreatic cancer metastatic Pancreatic ductal adenocarcinoma Pancreatic ductal adenocarcinoma (PDAC) PDAC Pdac - pancreatic ductal adenocarcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    48 sites in 3 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Avera Cancer Institute Research

    RECRUITING

    Sioux Falls, South Dakota, 57105, United States

    Contact Email: •••••@•••••

  • Bayside Health

    RECRUITING

    Frankston East, Victoria, 3199, Australia

  • Blue Ridge Cancer Care

    RECRUITING

    Blacksburg, Virginia, 24060, United States

  • Calvary Mater Newcastle

    RECRUITING

    Waratah, New South Wales, 2298, Australia

  • Cancer Research South Australia

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • Caucasus Medical Centre

    RECRUITING

    Tbilisi, TB, 0160, Georgia

  • City of Hope

    RECRUITING

    Phoenix, Arizona, 85338, United States

    Contact Email: •••••@•••••

  • City of Hope

    RECRUITING

    Duarte, California, 91010, United States

  • City of Hope

    RECRUITING

    Chicago, Illinois, 60099, United States

  • Clearview Cancer Institute

    RECRUITING

    Huntsville, Alabama, 35805, United States

  • Comprehensive Cancer Centers

    RECRUITING

    Las Vegas, Nevada, 89169, United States

  • FirstHealth of the Carolinas

    RECRUITING

    Pinehurst, North Carolina, 28374, United States

  • Florida Cancer Specialists - East

    RECRUITING

    West Palm Beach, Florida, 33401, United States

    Contact Email: •••••@•••••

  • Florida Cancer Specialists - North

    RECRUITING

    St. Petersburg, Florida, 33701, United States

    Contact Email: •••••@•••••

  • Florida Cancer Specialists - South

    RECRUITING

    Sarasota, Florida, 34239, United States

    Contact Email: •••••@•••••

  • Genesiscare

    RECRUITING

    Waratah, New South Wales, 2298, Australia

  • Hematology Oncology Associates of the Treasure Coast

    RECRUITING

    Port Saint Lucie, Florida, 34952, United States

  • Icon Cancer Centre - Chermside

    RECRUITING

    Chermside, Queensland, 4032, Australia

    Contact Email: •••••@•••••

  • Illinois Cancer Specialists

    RECRUITING

    Arlington Heights, Illinois, 60005, United States

  • LTD "Multiprofile Clinic Consilium Medulla"

    RECRUITING

    Tbilisi, TB, 0186, Georgia

  • Maryland Oncology

    RECRUITING

    Columbia, Maryland, 21044, United States

  • Medical Oncology Hematology Consultants

    RECRUITING

    Newark, Delaware, 19713, United States

  • Memorial Sloan Kettering Cancer Center

    RECRUITING

    New York, New York, 10065, United States

  • Missouri Cancer Associates

    RECRUITING

    Columbia, Missouri, 65201, United States

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

  • Northwest Cancer Specialists

    RECRUITING

    Vancouver, Washington, 98684, United States

  • OSF Medical Center

    RECRUITING

    Peoria, Illinois, 61603, United States

  • Piedmont Cancer Institute

    RECRUITING

    Atlanta, Georgia, 30318, United States

  • Piedmont Healthcare

    RECRUITING

    Atlanta, Georgia, 30318, United States

  • Poudre Valley Health Care, Inc

    RECRUITING

    Fort Collins, Colorado, 80528, United States

  • Princess Alexandra Hospital

    RECRUITING

    Woolloongabba, Queensland, 4102, Australia

  • Regional Cancer Care

    RECRUITING

    Belleville, New Jersey, 07109, United States

  • Rocky Mountain Cancer Centers

    RECRUITING

    Lone Tree, Colorado, 80124, United States

  • Sarah Cannon Research Institute

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Taylor Cancer Research Center

    RECRUITING

    Maumee, Ohio, 43537, United States

  • Tennessee Oncology

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Texas Oncology - Austin

    RECRUITING

    Austin, Texas, 78705, United States

  • Texas Oncology - San Antonio

    RECRUITING

    San Antonio, Texas, 78240, United States

  • Texas Oncology - West Texas

    RECRUITING

    Abilene, Texas, 79606, United States

  • Texas Oncology Gulf Coast

    RECRUITING

    Webster, Texas, 77598, United States

  • Thomas Jefferson University

    RECRUITING

    Philadelphia, Pennsylvania, 19107, United States

    Contact Email: •••••@•••••

  • University of California San Diego

    RECRUITING

    San Diego, California, 92037, United States

  • University of Kansas Cancer Center

    RECRUITING

    Fairway, Kansas, 66205, United States

  • University of Washington Fred Hutchinson Cancer Center

    RECRUITING

    Seattle, Washington, 98109, United States

    Contact Email: •••••@•••••

  • University of Wisconsin Carbone Cancer Center

    RECRUITING

    Madison, Wisconsin, 53792, United States

    Contact Email: •••••@•••••

  • Virginia Cancer Specialists

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact Email: •••••@•••••

  • West Cancer Center

    RECRUITING

    Germantown, Tennessee, 38138, United States

  • Willamette Valley Cancer Institute

    RECRUITING

    Eugene, Oregon, 97401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.